HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
The HDL hypothesis stating that simply raising HDL cholesterol (HDL-C) may produce cardiovascular benefits has been questioned recently based on several randomized clinical trials using CETP inhibitors or niacin to raise HDL-C levels. However extensive pre-clinical data support the vascular protect...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2015-09-01
|
| Sarja: | Frontiers in Pharmacology |
| Aiheet: | |
| Linkit: | http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00187/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|